The Offering at a glance
- Offer size
Up to 4,736,835 new shares of common stock and up to 3,068,165 existing shares of common stock - Selling Shareholders
Funds managed by private equity firms, MPM Capital, TVM Capital, Star Ventures and Alpinvest Partners Members of management board and employees to cover exercise price and tax resulting from the exercise of stock options - Novartis participation
Up to EUR 30 million of common stock in connection with the marketing and distribution partnership for the Japanese Encephalitis Vaccine - Offer and subscription period
June 14, 2006 to June 29, 2006 - Preferential Allocation
In the public offering in Austria, preferential allocation will be given to the first 750 shares of any retail order placed no later than 5:00 pm CEST on June 26, 2006. - Over-allotment option
Certain of the selling shareholders will grant an option to the initial purchasers to purchase up to 1,142,848 additional shares of common stock at the subscription and offering price solely to cover any over-allotments by Merrill Lynch International as stabilization manager. - Settlement date
July 4, 2006 - ISIN
AT 0000612601 - Vienna Stock Exchange ticker symbol
ICLL
